Harnessing traditional medicine and biomarker-driven approaches to counteract Trichostatin A-induced esophageal cancer progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed.

1. A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen.Medicine · 2025
   Trial
2. Actin gamma smooth muscle 2 drives proliferation, metastasis, and 5-Fluorouracil resistance in gastric cancer: insights from a Recurrence-Related Gene Signature.Cancer cell international · 2026
   Article
3. The ATG14: multi-layer autophagy control and an emerging therapeutic target in cancer.Apoptosis : an international journal on programmed cell death · 2026
   Review
4. RNA sequence analysis of differentially expressed genes in left atrial appendage thrombus.Journal of thrombosis and thrombolysis · 2026
   Article
5. Indigestible carbohydrates suppress colorectal cancer through IRF6/TRAF3/IFNα pathway.Discover oncology · 2026
   Article
6. Establishment of Centrosome Amplification-Correlated Model to Evaluate the Tumor Immune Microenvironment and Prognosis of Patients with Glioblastoma.Current medicinal chemistry · 2026
   Article
7. Efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin formula for enhanced recovery after coronary artery bypass grafting: a propensity score-matched prospective cohort study.Frontiers in medicine · 2026
   Article
8. DrugSurvPlot: A Novel Web-Based Platform Harnessing Drug Sensitivity Scores as Molecular Biomarkers for Pan-Cancer Survival Prognosis.Current gene therapy · 2026
   Article
9. Molecular Docking and Single-Cell RNA-Seq Analysis IdentifyCurrent medicinal chemistry · 2026
   Article
10. Transient receptor potential melastatin 6 and transient receptor potential melastatin 6/7 antagonists suppress colon adenocarcinoma HT-29 cells.World journal of gastrointestinal oncology · 2025
    Article
11. METTL3-mediated m6A methylation of LncRNA DUXAP8 promoted esophageal squamous cell carcinoma progression by activating the PI3K/AKT signaling pathway.Cell division · 2025
    Article
12. FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer.Discover oncology · 2025
    Article
13. LRP12 promotes gastric cancer progression through AKT/mTOR signaling and M2 macrophage-mediated immunosuppression.Scientific reports · 2025
    Article
14. MiR-5095 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting CEACAM5.Scientific reports · 2025
    Article
15. The global burden and trends of esophageal cancer caused by smoking among men from 1990 to 2021 and projections to 2040: An analysis of the Global Burden of Disease 2021.European journal of medical research · 2025
    Article
16. Identification of anoikis-related tumor microenvironment characteristics and prognostic signature in ovarian cancer at bulk and single-cell levels.Discover oncology · 2025
    Article
17. Prognostic value of Linc00662/miR-16-5p/FASN in cervical cancer and regulation of tumor progression.Hereditas · 2025
    Article
18. The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637.Hereditas · 2025
    Article
19. Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.Frontiers in immunology · 2025
    Article
20. Targeting GABA signaling in the tumor microenvironment: implications for immune cell regulation and immunotherapy resistance.Frontiers in immunology · 2025
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as